These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Single i.v. ketamine augmentation of newly initiated escitalopram for major depression: results from a randomized, placebo-controlled 4-week study. Hu YD; Xiang YT; Fang JX; Zu S; Sha S; Shi H; Ungvari GS; Correll CU; Chiu HF; Xue Y; Tian TF; Wu AS; Ma X; Wang G Psychol Med; 2016 Feb; 46(3):623-35. PubMed ID: 26478208 [TBL] [Abstract][Full Text] [Related]
5. Double-blind comparison of escitalopram and duloxetine in the acute treatment of major depressive disorder. Khan A; Bose A; Alexopoulos GS; Gommoll C; Li D; Gandhi C Clin Drug Investig; 2007; 27(7):481-92. PubMed ID: 17563128 [TBL] [Abstract][Full Text] [Related]
6. The impact of chronic depression on acute and long-term outcomes in a randomized trial comparing selective serotonin reuptake inhibitor monotherapy versus each of 2 different antidepressant medication combinations. Sung SC; Haley CL; Wisniewski SR; Fava M; Nierenberg AA; Warden D; Morris DW; Kurian BT; Trivedi MH; Rush AJ; J Clin Psychiatry; 2012 Jul; 73(7):967-76. PubMed ID: 22687487 [TBL] [Abstract][Full Text] [Related]
7. Escitalopram for severe asthma and major depressive disorder: a randomized, double-blind, placebo-controlled proof-of-concept study. Brown ES; Howard C; Khan DA; Carmody TJ Psychosomatics; 2012; 53(1):75-80. PubMed ID: 22221724 [TBL] [Abstract][Full Text] [Related]
8. Efficacy and tolerability of escitalopram versus citalopram in major depressive disorder: a 6-week, multicenter, prospective, randomized, double-blind, active-controlled study in adult outpatients. Yevtushenko VY; Belous AI; Yevtushenko YG; Gusinin SE; Buzik OJ; Agibalova TV Clin Ther; 2007 Nov; 29(11):2319-32. PubMed ID: 18158074 [TBL] [Abstract][Full Text] [Related]
9. Increased global integration in the brain after psilocybin therapy for depression. Daws RE; Timmermann C; Giribaldi B; Sexton JD; Wall MB; Erritzoe D; Roseman L; Nutt D; Carhart-Harris R Nat Med; 2022 Apr; 28(4):844-851. PubMed ID: 35411074 [TBL] [Abstract][Full Text] [Related]
10. Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression. Goodwin GM; Aaronson ST; Alvarez O; Arden PC; Baker A; Bennett JC; Bird C; Blom RE; Brennan C; Brusch D; Burke L; Campbell-Coker K; Carhart-Harris R; Cattell J; Daniel A; DeBattista C; Dunlop BW; Eisen K; Feifel D; Forbes M; Haumann HM; Hellerstein DJ; Hoppe AI; Husain MI; Jelen LA; Kamphuis J; Kawasaki J; Kelly JR; Key RE; Kishon R; Knatz Peck S; Knight G; Koolen MHB; Lean M; Licht RW; Maples-Keller JL; Mars J; Marwood L; McElhiney MC; Miller TL; Mirow A; Mistry S; Mletzko-Crowe T; Modlin LN; Nielsen RE; Nielson EM; Offerhaus SR; O'Keane V; Páleníček T; Printz D; Rademaker MC; van Reemst A; Reinholdt F; Repantis D; Rucker J; Rudow S; Ruffell S; Rush AJ; Schoevers RA; Seynaeve M; Shao S; Soares JC; Somers M; Stansfield SC; Sterling D; Strockis A; Tsai J; Visser L; Wahba M; Williams S; Young AH; Ywema P; Zisook S; Malievskaia E N Engl J Med; 2022 Nov; 387(18):1637-1648. PubMed ID: 36322843 [TBL] [Abstract][Full Text] [Related]
11. Bupropion extended release compared with escitalopram: effects on sexual functioning and antidepressant efficacy in 2 randomized, double-blind, placebo-controlled studies. Clayton AH; Croft HA; Horrigan JP; Wightman DS; Krishen A; Richard NE; Modell JG J Clin Psychiatry; 2006 May; 67(5):736-46. PubMed ID: 16841623 [TBL] [Abstract][Full Text] [Related]
12. A Randomized, Double-Blind, Placebo-Controlled Trial of Escitalopram in Patients with Asthma and Major Depressive Disorder. Brown ES; Sayed N; Van Enkevort E; Kulikova A; Nakamura A; Khan DA; Ivleva EI; Sunderajan P; Bender BG; Holmes T J Allergy Clin Immunol Pract; 2018; 6(5):1604-1612. PubMed ID: 29409976 [TBL] [Abstract][Full Text] [Related]
13. Symptomatic and Functional Outcomes and Early Prediction of Response to Escitalopram Monotherapy and Sequential Adjunctive Aripiprazole Therapy in Patients With Major Depressive Disorder: A CAN-BIND-1 Report. Kennedy SH; Lam RW; Rotzinger S; Milev RV; Blier P; Downar J; Evans KR; Farzan F; Foster JA; Frey BN; Giacobbe P; Hall GB; Harkness KL; Hassel S; Ismail Z; Leri F; McInerney S; MacQueen GM; Minuzzi L; Müller DJ; Parikh SV; Placenza FM; Quilty LC; Ravindran AV; Sassi RB; Soares CN; Strother SC; Turecki G; Vaccarino AL; Vila-Rodriguez F; Yu J; Uher R; J Clin Psychiatry; 2019 Feb; 80(2):. PubMed ID: 30840787 [TBL] [Abstract][Full Text] [Related]
14. Psilocybin with psychological support for treatment-resistant depression: six-month follow-up. Carhart-Harris RL; Bolstridge M; Day CMJ; Rucker J; Watts R; Erritzoe DE; Kaelen M; Giribaldi B; Bloomfield M; Pilling S; Rickard JA; Forbes B; Feilding A; Taylor D; Curran HV; Nutt DJ Psychopharmacology (Berl); 2018 Feb; 235(2):399-408. PubMed ID: 29119217 [TBL] [Abstract][Full Text] [Related]
15. Single-Dose Synthetic Psilocybin With Psychotherapy for Treatment-Resistant Bipolar Type II Major Depressive Episodes: A Nonrandomized Open-Label Trial. Aaronson ST; van der Vaart A; Miller T; LaPratt J; Swartz K; Shoultz A; Lauterbach M; Sackeim HA; Suppes T JAMA Psychiatry; 2024 Jun; 81(6):555-562. PubMed ID: 38055270 [TBL] [Abstract][Full Text] [Related]
16. Identification of Baseline Characteristics Associated With Development of Depression Among Patients With Head and Neck Cancer: A Secondary Analysis of a Randomized Clinical Trial. Panwar A; Rieke K; Burke WJ; Sayles H; Lydiatt WM; JAMA Otolaryngol Head Neck Surg; 2018 Nov; 144(11):1004-1010. PubMed ID: 30286230 [TBL] [Abstract][Full Text] [Related]
17. Reevaluating the Efficacy and Predictability of Antidepressant Treatments: A Symptom Clustering Approach. Chekroud AM; Gueorguieva R; Krumholz HM; Trivedi MH; Krystal JH; McCarthy G JAMA Psychiatry; 2017 Apr; 74(4):370-378. PubMed ID: 28241180 [TBL] [Abstract][Full Text] [Related]
18. Comparative oral monotherapy of psilocybin, lysergic acid diethylamide, 3,4-methylenedioxymethamphetamine, ayahuasca, and escitalopram for depressive symptoms: systematic review and Bayesian network meta-analysis. Hsu TW; Tsai CK; Kao YC; Thompson T; Carvalho AF; Yang FC; Tseng PT; Hsu CW; Yu CL; Tu YK; Liang CS BMJ; 2024 Aug; 386():e078607. PubMed ID: 39168500 [TBL] [Abstract][Full Text] [Related]
19. Escitalopram for the prevention of peginterferon-α2a-associated depression in hepatitis C virus-infected patients without previous psychiatric disease: a randomized trial. Schaefer M; Sarkar R; Knop V; Effenberger S; Friebe A; Heinze L; Spengler U; Schlaepfer T; Reimer J; Buggisch P; Ockenga J; Link R; Rentrop M; Weidenbach H; Fromm G; Lieb K; Baumert TF; Heinz A; Discher T; Neumann K; Zeuzem S; Berg T Ann Intern Med; 2012 Jul; 157(2):94-103. PubMed ID: 22801672 [TBL] [Abstract][Full Text] [Related]
20. Escitalopram and duloxetine in major depressive disorder: a pharmacoeconomic comparison using UK cost data. Wade AG; Fernández JL; François C; Hansen K; Danchenko N; Despiegel N Pharmacoeconomics; 2008; 26(11):969-81. PubMed ID: 18850765 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]